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adherence to diabetes medications than the comparison group (p=0.15). After the 
program, percent adherent grew 29.7% over baseline (p<0.01) net of trends in the 
comparison group. A smaller impact was observed for cardiovascular 
medications. Total spending (employer spending plus patient out-of-pocket 
spending) in the value-based program group was no different than the 
comparison group (p=0.11). Falsification tests of asthma and migraine 
medication utilization, showed no significant impact (p>.50). CONCLUSIONS: 
Results through the first twelve months of the program show that waiving 
copayments for all family members of a patient with diabetes can improve 
adherence to diabetes and cardiovascular services, which can lead to 
improvements in health outcomes.  
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BEYOND AVERAGE ADHERENCE: TEMPORAL PATTERNS OF MEDICATION 
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OBJECTIVES: A patient’s temporal pattern of medication adherence may contain 
signals for clinical risks that are not captured by aggregate measures such as the 
medication possession ratio (MPR). We used hierarchical clustering to identify 
natural adherence patterns to dornase alfa in patients with cystic fibrosis (CF), 
and assessed whether these patterns were associated with hospitalization risk. 
METHODS: CF patients with a dornase alfa prescription followed by ≥1 year of 
health plan enrollment were identified in a national claims database (2005 - 
2011). Hierarchical clustering was used to identify common patterns of 
adherence over time based on prescription fills. To evaluate the clinical and 
economic meaningfulness of the clusters, their association with CF-related 
hospitalization risk was assessed using Poisson regression with adjustment for 
MPR and other characteristics. RESULTS: A total of 985 CF patients with ≥1 
prescription for dornase alfa were included. Average MPR was 45%. Half of the 
patients experienced hospitalization. Clustering identified six adherence 
patterns: 1) high; 2) low→high; 3) low →lower; 4) high→ow; 5) periodic; and 6) 
low. MPR distributions overlapped between clusters. In the Poisson regression, 
each 1% increase in MPR was significantly (p<0.05) associated with an 
approximate 1% reduction in hospitalization risk. Including effects of cluster 
membership into the model with MPR significantly improved fit (P<0.001). Even 
after adjusting for MPR, hospitalization risk varied significantly across clusters, 
and, relative to cluster 1, was increased by 97%, 115%, 52%, 286% and 57% in 
clusters 2 through 6, respectively. The predictive significance of the clusters was 
robust to further adjustment for quadratic effects of MPR. CONCLUSIONS: In this 
study of CF patients, temporal patterns of medication adherence predicted 
hospitalization risk more accurately than MPR alone. Temporal adherence 
patterns beyond MPR may have clinical and economic utility across therapeutic 
areas and warrant further study.  
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OBJECTIVES: Medication non-adherence is a complex phenomenon that requires 
tailored interventions to improve it. A new self-reported measure of medication 
non-adherence was developed based on the commonly reported reasons 
underlying non-adherence. The goal of the new scale was to match the items in 
the scale with tailored interventions. The objectives of this study were to revise 
the original Medication Adherence Reasons Scale (MAR-Scale) based on expert 
opinion and cognitive interviewing and establish the psychometric properties of 
the scale. METHODS: A cross sectional design was used in collaboration with the 
Intermountain Medical Center Outpatient clinic for cholesterol lowering (CLM) 
and asthma maintenance medications (AMM). The study was conducted in two 
phases: Phase 1 - the original MAR-Scale was revised based on expert opinion 
and cognitive interviewing, Phase 2 - the revised MAR-Scale was tested for 
psychometric properties in a random sample of 350 subjects each on CLM and 
AMM. RESULTS: Revisions were made based on expert opinion that included 
asking a global question about adherence in the past 7 days, simplifying the 
items and converting them into first person sentences, objective anchoring of 
the scale, and expanding the “forgetfulness” item. Cognitive interviewing added 
one additional item to the survey. The MAR- Scale identified 48% of the CLM 
respondents and 65% of the AMM respondents as non-adherents. An exploratory 
factor analysis identified four domains in each medication with Cronbach alpha 
ranging from 0.848 to 0.953 in CLM and 0.827 to 0.891 in AMM. For validity, the 
scale exhibited significant correlations (0.434 for CLM and 0.539 for AMM at 
p<0.01) with the well validated Morisky scale and also had significant negative 
correlation with self-efficacy (-0.226 for CLM and -0.329 for AMM at p < 0.01). 
CONCLUSIONS: The study resulted in a revised MAR-Scale that demonstrated 
better psychometric properties than the original scale.  
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OBJECTIVES: It is well-established that patients’ medication adherence is often 
suboptimal and variable in chronic disease settings, but less is known about the 
association between adherence and outcomes, in part due to potential 
confounding by unobserved disease severity when using claims data. Our 
objective was to estimate adherence unexplained by observed characteristics 
and use this estimate to proxy severity, which could motivate better adherence 
but also worsen outcomes. METHODS: A sample of the IMS LifeLink Health Plan 
Claims Database was used to identify a cohort of 26,893 primary prevention 
statin users. Adherence was estimated as the yearly proportion of days covered 
in beginning with the index statin prescription. A finite mixture model (FMM) 
was used to predict a posteriori the membership to better or worse adherer types. 
Using OLS regression adjusting for patient characteristics and the ‘healthy 
adherer effect’, the determinants of this probability were estimated. A residual 
inclusion estimation approach was used in a Cox proportional hazards model to 
estimate the effect of adherence on cardiovascular events. RESULTS: In a sample 
of new statin users, groups of low- and high-adherers existed. While year one 
adherence was not associated with cardiovascular events, year two mean 
adherence was (0.49 vs. 0.46, P<0.001). In the second year of statin use, the 
probability of being a high-adherer increased for males, those over 65 years and 
‘healthy adherers’. The Cox model adjusting for the covariates and residuals 
showed that as year two adherence increased, CV hazard decreased by 38% 
(P>0.001), versus a 20% reduction when the residual was not included. The 
included residuals per se increased hazard by 28% (P=0.04), consistent with a 
disease severity effect. CONCLUSIONS: FMM estimation reveals adherence 
‘types’. Estimating the probability of the ‘type’ allows isolation of a measure to 
address unobserved characteristics, such as disease severity, when modeling 
outcomes.  
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OBJECTIVES: Accurately forecasting future disease prevalence and resulting 
demand for pharmaceuticals requires modeling changes in demographics, 
economic considerations, health care policy, disease risk factors, and treatment 
options. This study forecasts future neurological condition prevalence and 
related use of prescribed medications. METHODS: Using a microsimulation 
approach, we model future prevalence of neurological conditions and 
pharmaceutical use for each person in a stratified random sample (n~3M) of the 
population in the United States. The population database uses statistical 
matching to combine (1) population and economic data from the American 
Community Survey, (2) health data from the Behavioral Risk Factor Surveillance 
System, and (3) health data from National Nursing Home Survey. Sample 
weighting is derived from Census Bureau population projections. Logistic 
regression analysis with the Medical Expenditure Panel Survey estimates the 
propensity of people with neurological conditions to use prescribed medications 
to treat Alzheimer’s, attention deficit hyperactivity disorder, cerebral 
degeneration, epilepsy, extrapyramidal disease not elsewhere classified, mental 
retardation, migraine, mononeuritis of limb, multiple sclerosis, Parkinson’s, and 
sleep disorders. Forecasts through 2030 consider household income and 
demographic trends, and improved medical coverage under health care reform. 
RESULTS: In 2012, 26.6 million people (9% of US population) had a diagnosed 
neurological condition. Between 2012 and 2030, the population with neurological 
conditions will grow by 17% with the largest percentage growth occurring in 
Arizona (62% growth), Nevada (56%), and Florida (55%). Conditions with the 
largest percentage growth in prevalence are cerebral degeneration (72% growth), 
Parkinson’s disease (60%) and Alzheimer’s disease (59%). Use of medications will 
grow 2-3% through expanded medical coverage under PPACA. CONCLUSIONS: 
Prevalence rates for diagnosed and treated neurological conditions are projected 
to grow at similar rates over the next 20 years. Given the large increase in 
prevalence, the utilization of treatments (e.g., levodopa, MAOIs, cholinesterase 
inhibitors, and memantine) will rise accordingly.  
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Frequentist statistics typically examines the null hypothesis that no difference 
exists between the competing strategies. Bayesian statistics permits the 
calculation of the probability that a treatment is superior based on observed data 
and prior information. Output of Bayesian analysis allows the observation of 
how prior information affects the output, especially as new information builds 
on the prior information. OBJECTIVES: To further analyze using Bayesian 
methods clinical trial results for the treatment of asymptomatic carotid artery 
stenosis (surgery vs. medical management) whose results were previously 
reported using frequentist methods. METHODS: The outcome of interest was the 
mean difference in the probability of stroke or perioperative death between 
carotid endarterectomy (CEA) and aggressive medical management (AMM). The 
prior distribution came from the results of the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The likelihood distribution was sourced from the 
Asymptomatic Carotid Surgery Trial (ACST). The Metropolis-Hastings Markov 
chain Monte Carlo sampling algorithm was used to approximate the posterior 
distribution. A 4% mean difference was chosen as the threshold for clinical-
economic significance. In sensitivity analysis, the prior distribution was replaced 
with results of The European Carotid Surgery Trialists Collaborative Group (ECST) 
study. RESULTS: The likelihood distribution (ASCT results) had an 86.5% 
